Myovant Sciences Ltd

NYSE:MYOV   3:59:43 PM EDT
21.26
+0.87 (+4.27%)
4:00:00 PM EDT: $21.21 -0.05 (-0.24%)
Products

FDA Approves First Oral Hormone Therapy For Treating Advanced Prostate Cancer

Published: 12/18/2020 17:34 GMT
Myovant Sciences Ltd (MYOV) - FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer.
FDA Approved Orgovyx (relugolix) for the Treatment of Adult Patients With Advanced Prostate Cancer.